TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

Company Overview

TriSalus Life Sciences is an oncology company focused on developing technologies and therapies for patients with liver and pancreatic tumors. The company’s approach combines investigational immunotherapies with drug-delivery technologies intended to improve treatment access to solid tumors, which can be difficult to reach through conventional systemic administration.

TriSalus is best known for its Pressure-Enabled Drug Delivery (PEDD) platform, which is designed to deliver medicines directly into tumors or their surrounding blood vessels by using controlled pressure. The company also develops related infusion systems and procedures for regional delivery, including the TriSalus SmartFlow system, an FDA-cleared device used in certain hepatic artery infusion procedures.

In addition to its device and delivery platforms, TriSalus is advancing an oncology pipeline that includes nelitolimod, an investigational immunotherapy designed to stimulate immune activity through the toll-like receptor 9 pathway. The company’s clinical development efforts have primarily focused on liver and pancreatic cancers, with research and commercial activities centered in the United States.

Key Stats

• Today's Range: $4.32 to $4.62
• 50-Day Range: $4.22 to $5.74
• 52-Week Range: $2.20 to $7.95
• Volume: 350,984 shs
• Average Volume: 419,101 shs
• Market Capitalization: $267.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.20
• Consensus Rating: Hold

TriSalus Life Sciences Stock Analysis - MarketRank™

TriSalus Life Sciences scored higher than 48% of companies evaluated by MarketBeat, and ranked 575th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

TriSalus Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

TriSalus Life Sciences has a consensus price target of $10.20, representing about 135.0% upside from its current price of $4.34.

Amount of Analyst Coverage

TriSalus Life Sciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TriSalus Life Sciences are expected to grow in the coming year, from ($0.53) to ($0.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TriSalus Life Sciences is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TriSalus Life Sciences is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.49% of the float of TriSalus Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

TriSalus Life Sciences has a short interest ratio ("days to cover") of 28.81, which indicates bearish sentiment.

Change versus previous month

Short interest in TriSalus Life Sciences has recently decreased by 9.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TriSalus Life Sciences does not currently pay a dividend.

Dividend Growth

TriSalus Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.48

News Sentiment

TriSalus Life Sciences has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for TriSalus Life Sciences this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for TLSI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TriSalus Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.30% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.58% of the stock of TriSalus Life Sciences is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:TLSI
• Previous Symbol: NASDAQ:TLSI
• CIK: 1826667
• Web: trisaluslifesci.com
• Phone: 888-321-5212
• Fax: N/A
• Employees: 102
• Year Founded: 2009

Price Target and Rating

• Average Price Target for TriSalus Life Sciences: $10.20
• High Price Target: $12.00
• Low Price Target: $7.00
• Potential Upside/Downside: +135.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.23 million
• Net Margins: -62.59%
• Pretax Margin: -62.56%
• Return on Equity: N/A
• Return on Assets: -64.47%

Debt

• Debt-to-Equity Ratio: 5.05
• Current Ratio: 5.35
• Quick Ratio: 4.97

Sales & Book Value

• Annual Sales: $45.15 million
• Price / Sales: 5.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.68) per share
• Price / Book: -6.38

Miscellaneous

• Outstanding Shares: 61,580,000
• Free Float: 51,538,000
• Market Cap: $267.26 million
• Optionable: Not Optionable
• Beta: 0.44